Senta Frol

Beyond Amyloid: Systemic and Brain Frailty as Determinants of Response to Anti-Amyloid Therapy in Alzheimer’s Disease—A Conceptual Review

Anti-amyloid therapy (AAT) with monoclonal antibodies (mAbs) modestly slow cognitive and functional decline in early Alzheimer’s disease (AD). However, both the magnitude of clinical benefit and the risk of treatment-related complications vary substantially even among patients wi...